Sector News

Daiichi Sankyo makes another big whack at U.S. sales operations

March 6, 2018
Life sciences

Daiichi Sankyo, which has struggled financially since losing exclusivity for its blood pressure drug Benicar, is again swinging the job-cutting ax in the U.S., cutting 280 jobs from its commercial operations.

The Japanese drugmaker last week said the jobs are being eliminated from various locations in the U.S., as it streamlines its business to fit its current U.S. portfolio and “prepare for its upcoming oncology pipeline.”

“Our priorities are to bring spending in line with revenue, shift resources to maximize Injectafer and our abuse-deterrent pain treatments, and prepare for exciting potential new treatments for patients with cancer being developed by our R&D organization,” Ken Keller, president of administrative and commercial for Daiichi Sankyo, said in a statement.

The cuts follow a downsizing of about 1,200 employees in the U.S. which culminated with the company melding its U.S. R&D and commercial operations in a new facility in Basking Ridge, New Jersey, in April 2016. About 700 employees from its former U.S. headquarters in Parsippany, New Jersey, and R&D in Edison, New Jersey, made that move.

Daiichi also closed a 170-person R&D facility in India last year and month later shuttered another in Japan with 150 employees.

Daiichi has been trying to remake itself since before losing patent protection on its $2.6 billion seller Benicar in 2016. It has been shifting away from primary care meds and toward specialty drugs such as its clot-fighting pill Savaysa, and Movantik, a constipation drug it markets with AstraZeneca.

Last year it also had to lay out $300 million to settle about 2,300 lawsuits tied to side effects of the blood pressure medication and several related drugs.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend